VanEck Pharmaceutical ETF
PPH
46 hedge funds and large institutions have $60.9M invested in VanEck Pharmaceutical ETF in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 12 increasing their positions, 15 reducing their positions, and 3 closing their positions.
190% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $473K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
2% more funds holding
Funds holding: 45 → 46 (+1)
7.69% less ownership
Funds ownership: 39.62% → 31.93% (-7.7%)
20% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 15
29% less capital invested
Capital invested by funds: $85.6M → $60.9M (-$24.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$5.91M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.5M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$375K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$341K |
| 5 |
CFGS
Concourse Financial Group Securities
Birmingham,
Alabama
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$21.8M |
| 2 |
Goldman Sachs
New York
|
-$14.8M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.38M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$1.11M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$88.6K |
PPH Hedge Fund Activity: Q1 2019 in Review
46 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q1 2019, worth a combined $60.9M — down 29% from $85.6M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PPH positions and 3 closed out — a net gain of 1 holder — while 12 added to existing stakes and 15 trimmed.
The largest buyer was Brinker Capital Investments, adding an estimated $5.91M. The largest seller was Meitav Investment House, cutting an estimated $21.8M.
- 46 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q1 2019, up from 45 in Q4 2018.
- Funds reported $60.9M of VanEck Pharmaceutical ETF stock for Q1 2019, down 29% quarter-over-quarter.
- 4 funds opened new VanEck Pharmaceutical ETF positions in Q1 2019 and 3 closed out, a net change of +1 holder.
- The largest VanEck Pharmaceutical ETF buyer in Q1 2019 was Brinker Capital Investments, an estimated $5.91M added.
- The largest VanEck Pharmaceutical ETF seller in Q1 2019 was Meitav Investment House, an estimated $21.8M sold.
Based on aggregated 13F filings for Q1 2019.